← Leaderboards
Jeffrey Isner
Caritas St. Elizabeth'S Medical Center
$1,754,501
Attributed
$1,754,501
Total exposure
4
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$3,430,470 · 5
By mechanism
P01$1,675,969 · 2
R01$1,028,324 · 2
R37$726,177 · 1
Top collaborators
No co-investigators on record.
Most similar at Caritas St. Elizabeth'S Medical Center
Same institution · by research overlap
- Douglas W Losordo$24,177,187
- Kathryn Hirst$203,012,967
- Allan H Ropper$437,341
- Takayuki Asahara$803,977
- Allan Ropper$0
Others in their field
Top investigators on “Angiogenesis”
- David Heimbrook · Leidos Biomedical Research, Inc.$75,067,502
- Steven Terry Rosen · Beckman Research Institute/City Of Hope$59,567,306
- Martin Friedlander · Scripps Research Institute$48,350,175
- Larry Arthur$33,866,306
- Michael Simons · Yale University$30,647,106
- Henry Shelton Earp · Univ Of North Carolina Chapel Hill$29,372,588
Research focus
AngiogenesisLaboratory RabbitVascular Endothelial Growth FactorsGene TherapyCell Growth RegulationCell ProliferationLaboratory RatVascular EndotheliumLaboratory MouseBone Marrow TransplantationCell DifferentiationBone MarrowCell MigrationBeta GalactosidaseCell CycleBlood VesselsGrowth FactorDiabetes MellitusCd34 MoleculeDisease /Disorder ModelEnzyme MechanismGene ExpressionCollateral CirculationCardiovascular Pharmacology
Grant awards (7)
POSTNATAL VASCULOGENESIS IN CARDIOVASCULAR DISEASE$377,635
R01 · FY2002 · HL
Center of Excellence in Gene Therapy$1,675,969
P01 · FY2001 · HL
THERAPEUTIC ANGIOGENESIS IN VASCULAR MEDICINE II$389,982
R37 · FY2001 · HL
VEGF gene transfer for diabetic neuropathy$0
P01 · FY2001 · HL
POSTNATAL VASCULOGENESIS IN CARDIOVASCULAR DISEASE$355,957
R01 · FY2000 · HL
THERAPEUTIC ANGIOGENESIS IN VASCULAR MEDICINE II$336,195
R37 · FY2000 · HL
RE ENDOTHELIALIZATION AND RESTENOSIS$294,732
R01 · FY2000 · HL